VPHIF (Valeo Pharma) Change In Receivables: $0.45 Mil (TTM As of Jul. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VPHIF Valeo Pharma Inc VPHIF
12 GF Score
Price $0.00
View Full Analysis

What is Valeo Pharma Change In Receivables?

Valeo Pharma VPHIF -99.00% 12 Change In Receivables is $0.45 Mil as of Jul. 2024. GuruFocus rates VPHIF with a GF Score™ of 12/100.

Valeo Pharma's change in receivables for the quarter that ended in Jul. 2024 was $0.61 Mil. It means Valeo Pharma's Accounts Receivable declined by $0.61 Mil from Apr. 2024 to Jul. 2024 .

Valeo Pharma's change in receivables for the fiscal year that ended in Oct. 2023 was $-0.83 Mil. It means Valeo Pharma's Accounts Receivable increased by $0.83 Mil from Oct. 2022 to Oct. 2023 .

Valeo Pharma's Accounts Receivable for the quarter that ended in Jul. 2024 was $3.34 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Valeo Pharma's Days Sales Outstanding for the three months ended in Jul. 2024 was 33.21.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Valeo Pharma's liquidation value for the three months ended in Jul. 2024 was $-59.94 Mil.

Valeo Pharma  (OTCPK:VPHIF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Valeo Pharma's Days Sales Outstanding for the quarter that ended in Jul. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=3.344/9.188*91
=33.21

2. In Ben Graham's calculation of liquidation value, Valeo Pharma's accounts receivable are only considered to be worth 75% of book value:

Valeo Pharma's liquidation value for the quarter that ended in Jul. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5.195-69.439+0.75 * 3.344+0.5 * 3.6
=-59.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma Change In Receivables Related Terms

Valeo Pharma Change In Receivables Historical Data

* Premium members only.

The historical data trend for Valeo Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma Change In Receivables Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Change In Receivables
Get a 7-Day Free Trial 0.18 -0.51 -0.47 -2.65 -0.83

Valeo Pharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 -0.88 1.07 -0.35 0.61
VPHIF
12GF Score
Valeo Pharma Inc VPHIF
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valeo Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.45 Mil mean?
Valeo Pharma (VPHIF) has a Change In Receivables of $0.45 Mil as of Jul. 2024. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Valeo Pharma and its competitors.
Is Valeo Pharma's Change In Receivables too high?
Valeo Pharma's current Change In Receivables is $0.45 Mil. Overall, Valeo Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Valeo Pharma's Change In Receivables compare to ZTS?
Valeo Pharma's Change In Receivables of $0.45 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Valeo Pharma and its competitors. Valeo Pharma's current Change In Receivables is $0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valeo Pharma stock overvalued right now?
Valeo Pharma (VPHIF) has a current Change In Receivables of $0.45 Mil. The current Change In Receivables is $0.45 Mil. Valeo Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Valeo Pharma (VPHIF), the current Change In Receivables is $0.45 Mil as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valeo Pharma Business Description

Address 16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
12GF Score

Get the complete analysis for VPHIF

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price